Interobserver variability in the radiological assessment of response to chemotherapy in glioma

Neurology

Volumn 60, Issue 5, 2003, Pages 826-830

  Vos, M J ^a   Uitdehaag, B M J ^a   Barkhof, F ^a   Heimans, J J ^a   Baayen, H C ^a   Boogerd, W ^b   Castelijns, J A ^a   Elkhuizen, P H M ^a   Postma, T J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; LOMUSTINE; PACLITAXEL; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION COEFFICIENT; FEMALE; GLIOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0037432287     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000049467.54667.92     Document Type: Article

References (25)

1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-2578.
2. Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001;19: 551-557.
3. Chisholm RA, Stenning S, Hawkins TD. The accuracy of volumetric measurement of high-grade gliomas. Clin Radiology 1989;40:17-21.
4. Joe BN, Fukui MB, Meltzer CC, et al. Brain tumor volume measurement: comparison of manual and semiautomated methods. Radiology 1999;212:811-816.
5. Clarke LP, Velthuizen RP, Clark M, et al. MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation. Magn Reson Imaging 1998;16:271-279.
6. Shi W, Wildrick DM, Sawaya R. Volumetric measurement of brain tumors from MR imaging. J Neurooncol 1998;37:87-93.
7. Vaidyanathan M, Clarke LP, Velthuizen RP, et al. Comparison of supervised MRI segmentation methods for tumor volume determination .during therapy. Magn Reson Imaging 1995;13:719-728.
8. Vaidyanathan M, Clarke LP, Hall LO, et al. Monitoring brain tumor response to therapy using MRI segmentation. Magn Reson Imaging 1997;15:323-334.
9. Velthuizen RP, Clarke LP, Phuphanich S, et al. Unsupervised measurement of brain tumor volume on MR images. J Magn Reson Imaging 1995;5:594-605.
10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
11. Perry JR, DeAngelis LM, Schold SC Jr, et al. Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 1997;49: 912-917.
12. Zeltzer PM, Friedman HS, Norris DG, Ragab AH. Criteria and definitions for response and relapse in children with brain tumors. Cancer 1985;56:1824-1826.
13. Brada M, Yung WKA. Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol 2000;27(suppl 6): S11-S19.
14. Byrne TN. Imaging of gliomas. Semin Oncol 1994;21:162-171.
15. Kaplan RS. Complexities, pitfalls, and strategies for evaluating brain tumor therapies. Curr Opin Oncol 1998;10:175-178.
16. Cairncross JG, Pexman JHW, Rathbone MP, DelMaestro RF. Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 1985;17:570-572.
17. Forsyth PAJ, Petrov E, Mahallati H, et al. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol 1997;15:2076-2081.
18. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377-384.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33;159-174.
20. Veldhuyzen van Zanten SJO, Hijdra A. Onderzoek naar variatie tussen waarnemers met behulp van kappa. Ned Tijdschr Geneeskd 1988;132: 199-202.
21. 18]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608-615.
22. 18]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-1782.
23. 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy? Nucl Med Commun 2000;21:259-267.
24. Roesdi MF, Postma TJ, Hoekstra OS, van Groeningen CJ, Wolbers JG, Heimans JJ. Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 1998;40:251-255.
25. Preul MC, Caramanos Z, Villemure JG, et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 2000;46:306-318.